Baran D T, Lichtman M A, Peck W A
J Clin Invest. 1972 Aug;51(8):2181-9. doi: 10.1172/JCI107025.
We have studied the transport of alpha-aminoisobutyric acid (AIB)-3-(14)C and its response to cortisol and cycloheximide in vitro in blood lymphocytes from untreated patients with chronic lymphocytic leukemia. The accumulation of AIB-3-(14)C increased in a linear fashion for 60 min, and reached an apparent steady state in 120 min. The initial rate of AIB accumulation (V(o)) varied from 1.1 to 10.2 mumoles/kg cell H(2)O per min in cells from 16 different patients; however, V(o) was reproducible in cells from five of six patients which were studied repeatedly over 1-9 months, and correlated positively with the lymphocyte count (r = 0.51, P = < 0.01). Virtually total inhibition of protein synthesis with cycloheximide was found to decrease the accumulation of AIB in cells from four patients which had high rates of AIB transport, but had no effect on transport in cells from four patients which accumulated AIB more slowly. These results indicate that active transport depends, in part, upon the presence of labile protein with a turnover rate which varies among different cell populations. Treatment with 10 muM cortisol for 240 min in vitro reduced the initial rate of AIB-3-(14)C accumulation (V(o)) by 43.4+/-4.1% (SE) (range, 9-66%) in cells from 16 patients. The degree of inhibition did not vary appreciably over a 9 month period in four of five patients. The effect of cortisol was proportional to its starting concentration, and developed at low concentrations (0.1-1.0 muM). Cortisol appears to decrease AIB accumulation by inhibiting active uptake, since it neither enhanced the exodus of AIB, nor inhibited apparently nonsaturable transport. Inhibition was noncompetitive in type, suggesting that cortisol decreases the total capacity of the active transport mechanism.Cortisol inhibited AIB transport indirectly by a process which involved de novo protein synthesis, since inhibition (a) appeared only after 60 min of treatment, (b) was present in treated cells which were subsequently incubated for 60 min in cortisol-free medium, and (c) failed to develop during simultaneous blockade of protein synthesis with cycloheximide, even when cycloheximide itself did not decrease AIB transport.
我们研究了α-氨基异丁酸(AIB)-3-(14)C在未经治疗的慢性淋巴细胞白血病患者血液淋巴细胞中的转运及其对皮质醇和环己酰亚胺的体外反应。AIB-3-(14)C的积累在60分钟内呈线性增加,并在120分钟时达到明显的稳态。16名不同患者的细胞中,AIB积累的初始速率(V(o))在每分钟1.1至10.2微摩尔/千克细胞H(2)O之间变化;然而,在6名患者中,有5名患者的细胞V(o)在1至9个月内反复研究时具有可重复性,并且与淋巴细胞计数呈正相关(r = 0.51,P = < 0.01)。发现用环己酰亚胺几乎完全抑制蛋白质合成可降低4名AIB转运速率高的患者细胞中AIB的积累,但对4名AIB积累较慢的患者细胞的转运没有影响。这些结果表明,主动转运部分取决于不稳定蛋白质的存在,其周转率在不同细胞群体中有所不同。在体外,用10μM皮质醇处理240分钟可使16名患者细胞中AIB-3-(14)C积累的初始速率(V(o))降低43.4±4.1%(标准误)(范围为9 - 66%)。在5名患者中的4名患者中,9个月期间抑制程度没有明显变化。皮质醇的作用与其起始浓度成正比,并且在低浓度(0.1 - 1.0μM)时就会出现。皮质醇似乎通过抑制主动摄取来降低AIB的积累,因为它既不增强AIB的外流,也不抑制明显非饱和性转运。抑制类型为非竞争性抑制,表明皮质醇降低了主动转运机制的总能力。皮质醇通过涉及从头合成蛋白质的过程间接抑制AIB转运,因为抑制作用(a)仅在处理60分钟后出现,(b)在随后在无皮质醇培养基中孵育60分钟的处理细胞中存在,并且(c)即使环己酰亚胺本身不降低AIB转运,在同时用环己酰亚胺阻断蛋白质合成期间也不会出现抑制作用。